Johnson & Johnson Innovative Medicine Pipeline Key Events in 2025*

POTENTIAL APPROVALS US/EU

PLANNED SUBMISSIONS US/EU

- US SIMPONI (golimumab)
- EU Pediatric Ulcerative Colitis (PURSUIT 2)
- us **TREMFYA (guselkumab)** Ulcerative Colitis Subcutaneous Induction (ASTRO)
- US TREMFYA (guselkumab) EU Crohn's Disease Subcutaneous
- us TREMFYA (guselkumab) Pediatric Psoriasis

(PROTOSTAR)

Induction (GRAVITI)

- US TREMFYA (guselkumab) EU Crohn's Disease (GALAXI)
- US **TREMFYA (guselkumab)** Pediatric Juvenile Psoriatic Arthritis
- TREMFYA (guselkumab) ^{EU} Ulcerative Colitis (QUASAR)
- STELARA (ustekinumab)
- EU Pediatric Crohn's Disease (UNITI JR)

- US **nipocalimab** EU Generalized Myasthenia Gravis (Vivacity MG3)
- ✓ US SPRAVATO (esketamine) Treatment Resistant Depression monotherapy (TRD4005)
 - us DARZALEX (daratumumab) ^{EU} Smoldering Multiple Myeloma (AQUILA)
 - US DARZALEX (daratumumab) EU Frontline multiple myeloma transplant ineligible (CEPHEUS)
 - us **RYBREVANT (amivantamab)** ^{EU} Subcutaneous (PALOMA-3)
 - IMBRUVICA (ibrutinib) ^{EU} Frontline MCL (Triangle)

Anemia (ENERGY)

US nipocalimab

TREMFYA (guselkumab) ^{EU} Ulcerative Colitis Subcutaneous Induction (ASTRO)

Warm Autoimmune Hemolytic

- us TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)
- TREMFYA (guselkumab) EU Pediatric Psoriasis (PROTOSTAR)
- US STELARA (ustekinumab) EU Pediatric Ulcerative Colitis (UNIFY JR)
- us STELARA (ustekinumab) Pediatric Crohn's Disease (UNITI JR)
- US icotrokinra EU Psoriasis (ICONIC)

- TAR-200 (RIS/gemcitabine plus us cetrelimab) Non Muscle Invasive Bladder Cancer (SunRISe-1)
- us **aticaprant** Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura)
 - nent for Major Non Small Cell Lung Cancer er with (MARIPOSA Final OS) ra)

Phase II

TREMFYA (guselkumab) Ulcerative Colitis Subcutaneous Induction (ASTRO)

POTENTIAL CLINICAL DATA PRESENTATIONS¹

AKEEGA (niraparib/abiraterone)

M1 Metastatic Castration-

Sensitive Prostate Cancer

RYBREVANT / LAZCLUZE

(AMPLITUDE)

- TREMFYA (guselkumab) Psoriatic Arthritis Structural Damage (APEX)
- TREMFYA (guselkumab) Pediatric Psoriasis (PROTOSTAR)
- icotrokinra Psoriasis (ICONIC-LEAD, ICONIC-TOTAL)
- icotrokinra Psoriasis (ICONIC-Advance1/2)
- aticaprant Adjunctive Treatment for Major Depressive Disorder with Anhedonia (Ventura 1)
- RPGR Gene Therapy Retinitis Pigmentosa (LUMEOS)


Phase I/ II

TAR-200 (RIS/gemcitabine plus cetrelimab) Non Muscle Invasive Bladder Cancer (SunRISe-1)

- RYBREVANT (amivantamab) Head and Neck Cancer (ORIGAMI-4)
- TALVEY + TECVAYLI Multiple Myeloma Relapsed/Refractory (RedirecTT-1)
- RYBREVANT (amivantamab) Colorectal Cancer (ORIGAMI-1 rightsided)
- JNJ-4804 Co-antibody Therapeutic Psoriatic Arthritis (AFFINITY)
- icotrokinra Ulcerative Colitis (ANTHEM)
- nipocalimab Combination Therapy Rheumatoid Arthritis (DAISY)

= Achieved

¹ In order to be on key events clinical presentation, data must be presented at a major medical meeting.



J&J